Retina

Need for accuracy results in optimisation of training for novice surgeons

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March

Allen Ho, MD, presented on the 12-month results of an mutation agnostic optogenetic programme at the ARVO 2024 meeting

Three leaders in glaucoma research, retina care and refractive surgery share their expertise

Incoming ARVO president SriniVas R. Sadda, MD, discussed major challenges in vision science research and how annual meetings inspire innovation in ophthalmology

The mutant huntingtin protein in tear fluid may have the potential to serve as an early marker of changes in Huntington disease

Paul Kayne, PhD gave an onsite overview of his poster at the 2024 ARVO meeting

At the ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Giulia Corradetti, MD about AMD

Paolo Silva, MD, speaks on the effect of diabetic retinopathy lesion location and long-term risk of progression

Barry Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California Irvine, speaks about his ARVO poster presentation

Qinqin Zhang, PhD, presented on a deep learning model for GA segmentation at this year's ARVO meeting

At this year's ARVO meeting, Ash Abbey, MD, presented 36-month data from the GALE study of pegcetacoplan

Study results indicate that maintaining control of blood pressure and hemoglobin A1c are key to preventing the onset of diabetic retinopathy

Study data demonstrated a significant correlation between visual function, structure and neurological impairment in an experimental autoimmune encephalomyelitis model

During the month of May, Prevent Blindness will offer fact sheets, videos and other resources for IRD education

Gildeuretinol halts Stargardt disease progression, study results indicate

The online tool shows vision loss simulations for diabetic macular oedema, diabetic retinopathy, age-related macular degeneration and other retinal diseases

Prof Tadayoni was a much-admired leader, researcher, surgeon and EURETINA President

Zeiss has secured regulatory approvals to acquire DORC and will shift focus to integration implementation

Multimodal imaging and a systemic work-up failed to identify any underlying disorder for the hemorrhages

In addition to the primary safety and tolerability endpoints, the study also saw signals of biological response from EXN407

Good news for patients: use of anti-complement therapies have caused the growth rate of GA lesions to decrease

Retina specialists Giuseppe Querques, MD, PhD, and Paolo Lanzetta, MD, debate at the Congress on Controversies in Ophthalmology

At this year's Congress on Controversies in Ophthalmology, keynote speaker Ursula Schmidt-Erfurth, MD, addressed the clinical use of artificial intelligence

Kiora also stated a Phase 2 trial of KIO-104 is expected to begin later this year